Literature DB >> 16496073

[Measuring disease activity for rheumatoid arthritis].

D Aletaha1, T Stamm, J Smolen.   

Abstract

Rheumatoid arthritis (RA) is the most common systemic inflammatory joint disease. It can be treated effectively with disease modifying antirheumatic drugs, and the currently propagated treatment strategy is to treat RA consequently, and revise the therapeutic approach frequently on the basis of proper disease activity evaluation. In the current review, we focus on the instruments and measures used in the assessment of RA disease activity. We will first consider the so-called core set measures of activity, prividing comprehensive overviews on joint count scales, global scales, pain scales, biomarkers, and functional assessment instruments. The second part of the review focuses on the value of composite measures of disease activity; a term under which we subsume activity indices using various formulae, self-assessment tools of disease activity, and response criteria. Among the inflammatory rheumatic diseases, RA is the one for which the most intensive research is done, and usually instruments that work for RA are further tested for other joint diseases. However, there is still a research agenda for the assessment of disease activity, even for RA. One important aspect is to assess the reliability and utility of all available instruments, including the very low end of disease activity, since remission has become an achievable goal. Another focus of disease activity assessment is to derive measures that work in clinical trials and in daily practice, but are also well understood by patients and physicians. This will further improve our ability to care for patients with RA consequently.

Entities:  

Mesh:

Year:  2006        PMID: 16496073     DOI: 10.1007/s00393-006-0041-8

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  77 in total

1.  A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures.

Authors:  J S Smolen; T Sokka; T Pincus; F C Breedveld
Journal:  Clin Exp Rheumatol       Date:  2003 Sep-Oct       Impact factor: 4.473

2.  Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials.

Authors:  D Aletaha; M M Ward
Journal:  Ann Rheum Dis       Date:  2005-06-23       Impact factor: 19.103

3.  Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis.

Authors:  D M van der Heijde; M A van't Hof; P L van Riel; M A van Leeuwen; M H van Rijswijk; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

Review 4.  The links between joint damage and disability in rheumatoid arthritis.

Authors:  D L Scott; K Pugner; K Kaarela; D V Doyle; A Woolf; J Holmes; K Hieke
Journal:  Rheumatology (Oxford)       Date:  2000-02       Impact factor: 7.580

5.  A simplified disease activity index for rheumatoid arthritis for use in clinical practice.

Authors:  J S Smolen; F C Breedveld; M H Schiff; J R Kalden; P Emery; G Eberl; P L van Riel; P Tugwell
Journal:  Rheumatology (Oxford)       Date:  2003-02       Impact factor: 7.580

6.  Reliability of grip strength, walking time and button test performed according to a standard protocol.

Authors:  T Pincus; R H Brooks; L F Callahan
Journal:  J Rheumatol       Date:  1991-07       Impact factor: 4.666

7.  Do self-reported arthritis symptom (RADAR) and health status (AIMS2) data provide duplicative or complementary information?

Authors:  J H Mason; R F Meenan; J J Anderson
Journal:  Arthritis Care Res       Date:  1992-09

8.  Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

Authors:  J S Smolen; J R Kalden; D L Scott; B Rozman; T K Kvien; A Larsen; I Loew-Friedrich; C Oed; R Rosenburg
Journal:  Lancet       Date:  1999-01-23       Impact factor: 79.321

9.  The assessment of disease activity in rheumatoid arthritis using a multivariate analysis.

Authors:  R K Mallya; B E Mace
Journal:  Rheumatol Rehabil       Date:  1981-02-01

10.  Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score.

Authors:  Daniel Aletaha; Valerie P K Nell; Tanja Stamm; Martin Uffmann; Stephan Pflugbeil; Klaus Machold; Josef S Smolen
Journal:  Arthritis Res Ther       Date:  2005-04-07       Impact factor: 5.156

View more
  3 in total

1.  [Quality in acute inpatient rheumatology 2021 : Current aspects of the KOBRA quality label of the Association of Rheumatological Acute Care Clinics].

Authors:  H-J Lakomek; M Rudwaleit; A Hentschel; B Broge; J Abrolat; F Bessler; B Hellmich; A Klemann; A Krause; M Klass; J Strunk; W Fiori; N Roeder; J Braun
Journal:  Z Rheumatol       Date:  2021-05-17       Impact factor: 1.372

Review 2.  Evidence for treating rheumatoid arthritis to target: results of a systematic literature search.

Authors:  Monika Schoels; Rachel Knevel; Daniel Aletaha; Johannes W J Bijlsma; Ferdinand C Breedveld; Dimitrios T Boumpas; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Maxime Dougados; Paul Emery; Desirée van der Heijde; Tom W J Huizinga; Joachim Kalden; Edward C Keystone; Tore K Kvien; Emilio Martin-Mola; Carlomaurizio Montecucco; Maarten de Wit; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2010-04       Impact factor: 19.103

3.  Comparison of patient- and clinician-reported outcome measures in lower back rehabilitation: introducing a new integrated performance measure (t2D).

Authors:  Andrej Zdravkovic; Vincent Grote; Michael Pirchl; Martin Stockinger; Richard Crevenna; Michael J Fischer
Journal:  Qual Life Res       Date:  2021-06-15       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.